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The current inability of clinical criteria to accurately identify the “at-risk group” for
Amyotrophic Lateral Sclerosis (ALS) development as well as its unknown etiology are
fueling the interest in biomarkers aimed at completing clinical approaches for the
diagnosis. The Glial cell line-derived neurotrophic factor (GDNF) is a diffusible peptide
critically involved in neuronal differentiation and survival. GDNF is largely studied in various
neurological and neuromuscular diseases, with a great interest in the peripheral nervous
system (PNS). The recent discovery of Amyloid Precursor Protein (APP)-dependent
GDNF regulation driving neuro-muscular junctions’ formation in APP null transgenic mice,
prompts to study whether neurodegeneration relies on loss or gain of APP function and
suggests that it could affect peripheral processes. Here, we explored a brand-new aspect
of the loss of trophic support in ALS by measuring GDNF, APP, soluble APP fragments
and Aβ peptides levels in SOD1WT or SOD1G93A transgenic mouse models of ALS and in
human biological fluids [i.e. serum and cerebrospinal fluid (CSF)] from ALS patients and
control subjects. Our results show that both GDNF and soluble APP fragments levels
are altered at the onset of motor deficits in mice and that their levels are also modified
in patient samples. This study indicates that both GDNF and soluble APPα represent
possible biomarkers for ALS.
Keywords: biomarker, neurodegeneration, glial cell line-derived neurotrophic factor (GDNF), amyloid precursor
protein (APP), amyotrophic lateral sclerosis (ALS)
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by the selective
and progressive loss of motor neurons from the motor cortex, brain stem, and spinal cord leading
tomuscle atrophy, irreversible paralysis and eventually death within 3–5 years from symptom onset
as a result of respiratory failure. Most patients are aged between 50 and 75 years at diagnosis
and ALS is mostly sporadic with 90% of the cases occurring without a family history of the
disease. Although the disease is considered a rare type of motor neuron neurodegeneration, by
2040 it has been estimated that around 400,000 patients will be diagnosed with ALS worldwide (1).
Currently approved treatments for the disease, i.e. Riluzole and Edaravone, extend survival by few
months and only mildly improve motor function. The inefficacy of the available treatments may be
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attributed to the fact that ALS is a heterogeneous disease.
Furthermore, the process of diagnosis is often delayed, mainly
because many parameters need to meet diagnostic criteria.
Understanding the pathophysiology of both familial and
sporadic ALS and finding specific biomarkers to accelerate
diagnosis could help in developing more effective treatments.
Trophic factors have been largely studied as potential therapeutic
targets for ALS because of their essential role in neuronal
development, motor neuron maintenance and survival (2).
Difficulties for growth factor-based therapies relate to the fact
that therapeutic intervention mostly occurs after the diagnosis,
thereby resulting as ineffective in counteracting the already
ongoing neurodegenerative process. In this regard, trophic
factors’ levels would rather be useful as biomarkers for diagnosis
and/or prognosis.
Interestingly, aside from their synthesis in the local
spinal/muscular microenvironment, trophic factors play
important roles in the nourishing feedback during which
originating neurons receive trophic input from their target
tissues (3). In ALS, it has been proposed that the failure of muscle
cells to release neurotrophic factors that maintain the favorable
physiological context for spinal motor neurons may lead to the
loss of that neuronal cell population (4).
The glial cell line-derived neurotrophic factor (GDNF) is
one of the factors produced by muscles and Schwann cells.
The absence of GDNF alters the location of developing spinal
motor neurons that innervate the limbs (5) and selectively
affects the innervation of intrafusal muscle spindles in mice (6).
Interestingly, the overexpression of this factor in muscle during
development causes a hyperinnervation of neuromuscular
junctions (7), while GDNF heterozygous mice (+/−) exhibit
locomotor deficiencies (8), suggesting that GDNF dosage
plays a key role in neuromuscular function. When GDNF is
administered directly in muscles, it preserves the muscle-nerve
synapse and promotes motor neuron function and survival in
a familial rat model of ALS (9). Furthermore, overexpression of
GDNF inmuscle extends lifespan in ALSmice (10). Interestingly,
GDNF can be retrogradely transported along motor neuronal
axons (11), thereby enabling to explore the relevance of the
intramuscular delivery route to act on both somas and nerve
endings.
Recently, we demonstrated that the Amyloid Precursor
Protein (APP) controls GDNF transcription in mouse embryonic
fibroblasts (MEFs) and muscles with an important impact
on muscular trophy and on the formation of neuromuscular
contacts (12). Together with others, our study suggests that
defects in APP function might be directly related not only to
Alzheimer’s disease (AD), but also to other neurodegenerative
diseases involving muscle denervation, such as ALS. Indeed, APP
is upregulated in muscle from mouse models of familial ALS
as well as from patients with ALS, where APP upregulation
correlates with clinical symptoms (13, 14).
In this study, we investigated in parallel the expression levels
of GDNF and APP and its metabolites in muscles from non-
transgenic mice and transgenic mice overexpressing the wild-
type human isoform of the Cu/Zn superoxide dismutase 1
(SOD1WT) enzyme or the mutant SOD1G93A protein, the latter
animals recapitulating much of the pathophysiology of ALS. We
analyzed APP processing by measuring the levels of its soluble
non-amyloidogenic fragments (sAPPα and sAPPβ) and amyloid-
β (Aβ peptides), together with GDNF levels, in cerebrospinal
fluid (CSF) and serum from ALS patients and healthy controls.
We found that both GDNF and APP levels are increased in
hindlimbs muscles of the transgenic SOD1G93A mouse model
of ALS at the onset of motor deficits. Alterations in GDNF and
sAPPα levels have been observed also in human biological fluids
from patients with a moderate and fast progression of the disease.
More precisely, GDNF levels are importantly decreased in the
serum of ALS patients while sAPPα levels are increased in the
same fluid, compared to healthy controls.
Altogether, our results suggest that both GDNF and sAPPα,
which are clearly involved in neuromuscular pathologies,
represent possible biomarkers for ALS pathophysiology.
MATERIALS AND METHODS
Mouse Models and Genotyping
Transgenic mice expressing human SOD1WT [B6SJL-Tg(SOD1)
2Gur/J–002298] or SOD1G93A [B6SJL-TgN(SOD1-G93A)
1Gur/J–002726] were purchased from The Jackson Laboratories.
Animal care and handling were performed according to the
European Council Directive 2010/63/EU and to the Italian and
Belgian Animal Welfare Act for the use and care of laboratory
animals and approved by the Animal Ethics Committee of the
Universite Catholique of Louvain.
Genotyping and Tissue Processing
Genomic DNA was extracted from mouse tail biopsies and
used as DNA template in genotyping PCR analysis. Offspring
positive for the SOD1G93A transgene were identified using the
following primers: SOD1, forward 5′-CATCAGCCCTAATCC
ATCTGA-3′ and reverse 5′-CGCGACTAACAATCAAAGTGA-
3
′
as described in Brambilla et al. (15). Hindlimbs muscles
(gastrocnemius and tibialis anterior) from transgenic mice were
snap frozen in liquid nitrogen and stored at −80◦C until further
use (RNA isolation for RT-qPCR and Western blotting).
RNA Preparation, RT-PCR, and
Quantitative PCR
RNAs were extracted from tissues in TRIzol Reagent and reverse
transcribed using an iScript cDNA Synthesis Kit (Bio-Rad).
Real-time quantitative PCR (qPCR) analysis was performed on
2ng cDNA template by using iQ SYBR Green Supermix in an
iCycler IQ Multicolor Real-Time PCR Detection System (Bio-
Rad). qPCR conditions were typically 95◦C for 30 s, followed by
40 cycles of 30 s at 95◦C, 45 s at 60◦C, and 15 s at 79◦C and
ended by 71 cycles of 30 s at 60◦C. The relative changes in the
target gene: glyceraldehyde 3-phosphate dehydrogenase mRNA
ratio were determined by the 2(−11Ct) calculation.
The sequences for qPCR primers are the following: GDNF,
forward 5′-TTAATGTCCAACTGGGGGTCT-3′ and reverse
5′-GCCGAGGGAGTGGTCTTC-3′; and glyceraldehyde 3-
phosphate dehydrogenase, forward 5′-ACCCAGAAGACTGTG
GATGG-3′ and reverse 5′-ACACATTGGGGGTAGGAACA-3′.
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Western Blotting
Muscles were homogenized in 10 volumes of lysis buffer [50mM
Tris (pH 7.5), 150mM NaCl, 0.05mM EDTA, 1% Triton X-
100, and 0.1% sodium dodecyl sulfate] with Complete Protease
Inhibitor Cocktail on ice using a Ultraturax homogenizer 3 ×
10 s for each sample and in between 30 s (or more) on ice to cool
down. After 1h at 4◦C with continuous rotation, samples were
centrifuged at 10,000 g for 10min at 4◦C and the supernatants
were collected. Protein concentration was determined by the
BCA Protein Assay Kit (Bio-Rad). A total of 15 µg protein
was heated for 10min at 70◦C in loading buffer (lysis buffer
containing 0.5M DTT and staining NuPAGE blue), loaded and
separated onto NuPAGE4–12% Bis-TrisGel, and then transferred
for 2 h at 30V onto PVDF membranes. After blocking (5%
nonfat milk in PBS-Tween 0.05%), membranes were incubated
overnight at 4◦C with the primary antibodies, washed, and
incubated with the secondary antibody coupled to peroxidase
prior to ECL detection (GEHealthcare). ECL signals were
quantified with a GelQuantNET software. Primary antibodies
included anti-APP Y188 (1:5,000) or GAPDH2 (1:25,000) in 5%
nonfat milk in PBS-Tween 0.05%. Secondary antibody included
anti-rabbit (1:10,000).
Study Group and Sampling
Venous serum samples and CSF were obtained from a group of
subjects consisting of 7 patients with sporadic ALS and 7 healthy
age-matched controls (CTR); clinical and demographic features
are summarized in Table 1. All the subjects were examined by
a senior neurologist and diagnosis of ALS was made according
to the El Escorial criteria (16). ALS was diagnosed based upon
symptom evaluation, neurological examination, laboratory and
brain and/or spinal cord magnetic resonance imaging. Disease
progression rates have been calculated as the ratio between
the functional scale and disease duration in months; < 0.5 is
considered slow; 0.5–1: moderate and>1: fast progression.
Control subjects were individuals with subjective complaints
but with no diagnosis of neurological or psychiatric disease. None
of the subjects selected in this study was affected by neoplastic
or autoimmune disease when the blood and CSF samples were
taken.
The patients had undergone a lumbar puncture and blood
sampling in the Neurology department of the Cliniques
Universitaires Saint-Luc (Brussels, Belgium) as part of the
routine diagnostic procedure. Patients admitted to this hospital
sign an internal regulatory document, stating that left-overs
from biological samples used for routine diagnostic procedures
can be used for retrospective academic studies, without
an additional informed consent (ethics committee approval
2007/10SEP/233). Haemorrhagic CSF samples were excluded.
CSF sample collection and storage were carried out in accordance
with the consensus protocol proposed by Teunissen et al.
(17). For serum studies, blood samples were collected in S-
Monovette R© 7.5ml Serum Z tube (ref. 01-1601, Sarstedt). Both
blood and CSF were centrifuged at 3600 rpm for 6min. Serum
and cell-free CSF were respectively aliquoted and stored at
−80◦C for later analysis.
GDNF, sAPP, and Aβ Measurements
Secreted GDNF levels were quantified in serum and CSF
from the study group by ELISA following the manufacturer’s
instructions (Promega). sAPPα and β and Aβ38, Aβ40, and Aβ42
peptides were quantified using a sAPPα/sAPPβ multiplex and an
Aβ multiplex electro-chemiluminescence immunoassay ECLIA
(Meso Scale Discovery), respectively. sAPPα and β and Aβ were
quantified according to the manufacturer’s instructions.
Statistical Analysis
The number of samples in each experimental condition is
indicated in the figure legends. Data were analyzed using
GraphPad Prism software (GraphPad Software, La Jolla, CA,
USA) by unpaired Student’s t-test (2 experimental conditions) or
by ANOVA followed by Bonferroni’s multiple comparison tests
(>2 experimental conditions).
RESULTS
We analyzed GDNF mRNA levels in hindlimbs muscles from
non-transgenic (NTg) or transgenic SOD1WT and SOD1G93A
mice at 30 (asymptomatic stage), ∼100 (onset of motor
deficits) and ∼130 days of age (symptomatic stage) (Figure 1).
GDNF mRNA levels remained below the detection limit at the
asymptomatic stage in all the mouse genotypes (data not shown).
A significant increase in GDNF mRNA levels in SOD1G93A
mice vs. NTg and SOD1WT mice was observed only at the
onset of motor deficits at 100 days (Figure 1A), and diminished
thereafter.
In the same tissues, we measured by Western blotting APP
levels, which showed a significant increase in its expression in
SOD1G93A mice at the onset of motor deficits. More specifically,
we found a 3.5-fold increase in APP levels in the hindlimb
muscles at 100 days of age in SOD1G93A mice compared to both
NTg and SOD1WT mice (Figures 1B,C). To note, the maturation
profile of APP was also sharply pronounced at this stage (APP
appearing as a doublet). This increase in APP expression levels
was not detectable in animals aged 30 days or 130 days. By
contrast, in NTg or SOD1WT APP levels remained low and
constant throughout the lifespan (Figures 1B,C).
Since ALS transgenic mouse models mimic the clinical
situation observed in patients, we analyzed both GDNF and
soluble APP fragments in biological fluids from controls subjects
and ALS patients. Group characteristics of study population are
shown in Table 1. The mean age of the control group was 58.6±
9.9 years (range 43–75 years) and that of ALS group was 64.1 ±
13.5 years (range 38–81 years). There was no significant statistical
difference between the groups (p = 0.398). The mean duration
of disease in ALS patients was 13.4 ± 15.7 months; the mean
ALSFRS-R and the Progression rate calculated at the diagnosis
were 41.7 ± 3 and 9.9 ± 15.1 respectively, indicating that ALS
patients were all fast progressors, with one intermediate and no
slow progressors.
We measured GDNF concentration in CSF and serum from
healthy subjects and ALS patients to follow their expression in
biological fluids reflecting the biochemical changes ongoing in
the brain and in the peripheral tissues, respectively. The median
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TABLE 1 | Demographic and clinical variables of the study group.
Patients Age range at collection (years) Onset L.O.I. until diagnosis (months) ALSFRS-R score Progression rate (point/month)
Control 1 56–61 NA NA NA NA
Control 2 60–65 NA NA NA NA
Control 3 40–45 NA NA NA NA
Control 4 60–65 NA NA NA NA
Control 5 70–75 NA NA NA NA
Control 6 50–55 NA NA NA NA
Control 7 50–55 NA NA NA NA
ALS 1 56–61 Bulbar 1 44 44
ALS 2 36–41 Bulbar + hemiparesis 6 43 7.2
ALS 3 66–71 Paraparesis 48 38 0.8
ALS 4 60–65 Bulbar + hemiparesis 8 37 4.6
ALS 5 70–75 Paraparesis 11 43 3.9
ALS 6 70–75 Bulbar 12 42 3.5
ALS 7 80–85 Paraparesis 8 45 5.6
L.O.I., Length of Illness; ALSFRS-R, ALS Functional Rating Scale-Revised; NA, Not applicable. Both the ALSFRS-R and the Progression rate were calculated at the diagnosis. The
references for the Progression Rate are: slow < 0.5, intermediate 0.5–1.0, fast >1.0.
of GDNF levels in CSF was higher in ALS patients (33.1 ±
20.5 pg/ml) compared to CTR (21.2 ± 4.3 pg/ml), but the
statistical significance was reached only in serum, where ALS
patients showed clearly lower levels of GDNF when compared
to CTR (107.3 ± 37.7 pg/ml vs. 198.1 ± 41 pg/ml, respectively).
These results (Figures 2A,B) were consistent with the decrease
in GDNF expression oberserved in SOD1G93A mouse muscles
at the advanced stage (Figure 1A). APP holoprotein cannot be
tracked in extracellular media. In order to analyse a potential
correlation with the amount of soluble APP levels in subjects’
biological fluids and GDNF levels, we measured by ECLIA the
soluble non-amyloidogenic fragments of APP: sAPPα and β, both
in CSF and serum (Figures 3A–D) and their ratio (Figures 3E,F)
that provides additional information about the equilibrium
between non-amyloidogenic and amyloidogenic APP processing.
Interestingly, the levels of sAPPαwere increased only in serum of
ALS patients compared to controls. No differences were observed
in CSF. To note, neither sAPPβ levels nor sAPPα/β ratio was
affected in serum or CSF of patients with ALS. Concerning the
levels of Aβ38, Aβ40, and Aβ42, in both CTR and ALS patients,
Aβ peptides were detectable only in CSF (Figure 4A), while
in serum Aβ levels were very low (Figure 4B). No significant
differences were observed in Aβ42/Aβ40 ratio (Figure 4C).
DISCUSSION
The lack of clinical criteria to accurately identify the “at-risk
group” for ALS development together with the unknown etiology
of the disease are fueling the interest in biomarkers aimed at
completing clinical approaches for the diagnosis and suitable as
new therapeutic targets. In this study, we explored specifically if
the loss of trophic support in neurodegenerative diseases could
provide bona fide biomarkers for ALS.Wemeasured GDNF, APP
as well as soluble APP fragments and Aβ peptides levels, inmouse
models of ALS and in human biological fluids (i.e., serum and
CSF) from patients and control subjects.
Glial cell line-derived neurotrophic factor is a diffusible
peptide critically involved in neuronal differentiation and
survival and it has been identified in an unbiased proteomic
assay as potential AD biomarker (18, 19). It has been evaluated
for symptomatic treatment of Parkinson’s disease (PD) (20),
and shown to be able to reverse some aspects of aging in
monkeys (21). Importantly, GDNF is particularly involved in
the pathophysiology of various neurological and neuromuscular
diseases, with a great interest in the peripheral nervous system
(PNS). GDNF has been reported to preserve motor neurons
from dying by using neural progenitor cells delivery (22) or
muscle-derived GDNF (23), suggesting that therapies targeting
GDNF could be efficient to cope with ALS. Here, we have
reported a clear alteration of GDNF levels both in muscles from
ALS mouse models and serum from ALS patients. We found
an increase in GDNF levels in muscle from mice expressing
the mutant isoform of SOD1G93A at the onset of symptoms
(100 days). Other groups observed an increased expression
of GDNF mRNA in skeletal muscle from patients (24–26).
The increment in GDNF mRNA levels in SOD1G93A mice is
concomitant to the onset of ALS symptoms (denervation) but
it is temporary. As it has been demonstrated in patients; GDNF
levels increase contemporary to denervation aiming to promote
potential reinnervation, but the reaction may be transient. We
believe that the decrease in GDNF mRNA levels observed at
day 130 might be due to the reduction in the total number
of muscle fibers, the low number of fibers in acute stages
of neurogenic atrophy and replacement of muscle fibers by
connective tissue occurring in later stages of the disease. The fact
that a similar reduction in GDNF mRNA levels is detected in
SOD1wt mice can be explained by the presence of motor neuron
pathology and skeletal muscle atrophy also in these animals
(27, 28).
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FIGURE 1 | GDNF and APP levels in non-transgenic and SOD1 transgenic mice models. (A) GDNF mRNA levels were analyzed in hindlimbs muscles from
non-transgenic (NTg), SOD1WT and SOD1G93A mice at ∼100 (onset of motor deficits) and ∼130 days of age (symptomatic stage). Values (mean ± SEM) are
expressed as percentage of age-matched NTg mice. **P < 0.01, ANOVA followed by Bonferroni post-hoc test, n = 3–4 mice per genotype and age. (B) APP levels
were analyzed by Western blotting in the same muscles’ lysates at 100 and 130 days, plus at 30 days (asymptomatic stage) in NTg, SOD1WT and SOD1G93A mice;
GAPDH2 was used as a loading control probe. Quantifications are shown in (C). Values (mean ± SEM) are expressed as percentage of expression level of
age-matched NTg mice. *P < 0.05 and #P < 0.05 vs. 100-day-old genotype-matched mice NTg and SOD1WT; ANOVA followed by Bonferroni post-hoc test, n =
3–4 mice per genotype and age.
FIGURE 2 | GDNF levels in biological fluids from CTR subjects and ALS patients. GDNF levels were quantified by ELISA in the CSF (A) and serum (B) of controls
without neurological disease and ALS patients. Values are given in picograms per milliliter (pg/ml). Each dot corresponds to one subject studied; the horizontal bar
indicates the mean in each group. **P < 0. 001, Student’s t-test (n = 7/group).
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FIGURE 3 | CSF and serum sAPPα, β and their ratio in CTR and ALS patients. sAPP α levels (A,B) and sAPP β (C,D) were quantified by ECLIA in the CSF and serum
of controls without neurological disease and ALS patients. sAPP α / sAPP β ratio have been showed for both CSF (E) and Serum (F). Values are given in nanograms
per milliliter (ng/ml). Each dot corresponds to one subject studied; the horizontal bar indicates the mean in each group. *P < 0.05, Student’s t-test (n = 7/group).
All together, these findings suggest that GDNF is importantly
synthetized by muscles to sustain the increased demand for
trophic factors by motor neurons, which are prone to degenerate
in ALS. Interestingly, we observed also a significant increment in
APP levels in mice expressing the mutant isoform of SOD1G93A
at the stage of disease onset (100 days). This is in line
with previously published work (13, 14). We recently found
that APP controls GDNF transcription in muscles, supporting
the neuromuscular phenotype observed in APP knock-out
(KO) mice (12). This result suggests that changes in APP
expression observed herein and in muscles of patients with
ALS (14), could directly affect muscular GDNF expression
and release. Thus, APP could not only be a biomarker of
ALS progression, but it could be involved in the pathways
controlling trophic supply that are impaired in the ALS
pathology.
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FIGURE 4 | CSF and serum Aβ38, Aβ40, and Aβ42 and Aβ42/Aβ40 ratio in CTR and ALS patients. Soluble monomeric Aβ38, Aβ40, and Aβ42 were quantified by
ECLIA in the CSF (A) and serum (B) of controls without neurological disease and ALS patients. (C) Aβ42/Aβ40 ratio have been showed for both CSF and Serum.
Values are given in nanograms per milliliter (ng/ml). Each dot corresponds to one subject studied (n = 7/group); the horizontal bar indicates the mean in each group.
In human samples, we observed significant and clear-
cut results in serum while we measured only tendencies of
impairment for both GDNF and APP metabolites in CSF.
More specifically, we recorded a trend of GDNF levels to
increase in the CSF of only 3 over 7 ALS patients, while a
uniform and significant decrease in serum from ALS patients
was detected. Our results indicate that peripheral GDNF (serum)
is decreased as consequence to the fact that the regulatory
system of GDNF production, likely involving APP, is no more
functional and therefore reflected by a decrease of GDNF in
serum. This is a peripheral process since central GDNF (CSF)
is not significantly affected in the pathology. In parallel, we
studied APP metabolite levels in the patient samples and we
observed a trend to decrease of sAPPα levels in the CSF of ALS
patients and a significant increase in sAPPα levels in serum from
patients. Interestingly, sAPPα has been suggested to have potent
neuroprotective capacities (29). Alterations in sAPPα levels in
peripheral fluids from patients could indicate that peripheral
mechanisms involving APP-dependent GDNF regulation may
be implicated in the disease. Same observations, though not
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statistically significant, hold true for sAPPβ while no differences
have been detected neither in sAPPα/sAPPβ ratio nor in Aβ
levels.
Aβ levels are one of the most extensively evaluated markers
of sporadic AD, since GDNF was identified as potential AD
biomarker (18, 19), could we suggest it as a general biomarker of
neurodegenerative diseases? The question is open. What is clear
is that in AD Aβ levels are importantly high, while in ALS there
are no alterations compared to age-matched control subjects at
any stage of the disease. This suggests that very likely, APP and
GDNF are linked in different neurodegenerative diseases but the
mechanistic aspects are peculiar to the specific disease and still
need to be decipher.
It is at this stage difficult to make clear-cut correlations
between GDNF and APP soluble fragments in human samples
because of the reduced number of ALS patients enrolled in
the study, the variability existing between them and especially
because of the peculiarity of disease history. Large scale studies on
bigger cohorts would be useful to elaborate on the observations
we made here. Clearly, both GDNF and soluble sAPPα levels
are altered in fluids from patients with intermediate and fast
progression of the disease, indicating that GDNF and soluble
APP are biomarkers of ALS pathophysiology. The unequivocal
observations in mouse muscles and serum from patients strongly
suggest that changes in APP and GDNF levels result from
peripheral processes. Assessing biomarkers in blood has the
great advantage of minimal invasiveness when compared to
measurement in CSF samples.
Changes in GDNF and sAPPα in serum go in opposite
directions leaving open the following question: is APP-dependant
GDNF expression involved in ALS progression, or are they
independent biomarkers? The correlation between APP-related
and GDNF changes, and their contribution to ALS pathways
need to be fully elucidated, in order to consider them as possible
targets for therapeutic approaches.
In conclusion, we suggest that the combined analysis of GDNF
and sAPPα that we propose as possible predictive peripheral
biomarkers for ALS, could help for the comprehension of the
etiopathogenesis and the improved precision of the diagnosis of
ALS.
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